https://pittplusme.org/study/1893
HCC 20-138: Triple-Negative Breast Cancer Study
STUDY BASICS
Have you been diagnosed with early-stage or advanced triple-negative breast cancer? You may be able to participate in a research study to find out if a new combination of anti-cancer study drugs is a safe and effective treatment for people with triple-negative breast cancer. Participation in this study may last up to 21 months.
STUDY PURPOSE
Triple-negative breast cancer is a type of breast cancer that does not have estrogen, progesterone, or HER-2 receptors. In some cases, triple-negative breast cancers can be difficult to treat.
The purpose of this study is to find out if a new combination of study drugs (tiragolumab, atezolizumab, and chemotherapy) is safe and effective for people with triple-negative breast cancer. The chemotherapy drugs are known as nab-paclitaxel, carboplatin, doxorubicin, and cyclophosphamide. Tiragolumab and atezolizumab are considered to be experimental in this study because they have not been FDA-approved for the treatment of triple-negative breast cancers.
COULD THIS STUDY BE RIGHT FOR YOU?
- Age 18 and up
- Diagnosed with early-stage or advanced triple-negative breast cancer
WHAT PARTICIPANTS CAN EXPECT
Participation in this research study may last up to 21 months. Study treatment depends on the stage of cancer and the study arm to which you are assigned.
IRB: SSU00132202
- F. Hoffmann-La Roche Ltd - CO42177 / CCO-US, A PHASE Ib, OPENLABEL, MULTICOHORT STUDY OF THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF TIRAGOLUMAB IN COMBINATION WITH ATEZOLIZUMAB AND CHEMOTHERAPY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER (Pro00044417)
MEET THE RESEARCHER
Leisha Emens
Leisha Emens, MD, PhD, is Professor of Medicine at the University of Pittsburgh, Co-Leader of the Hillman Cancer Immunology and Immunotherapy Program, and Director of Translational Immunotherapy for the Women's Cancer Research Center at Magee Women's Hospital. Dr. Emens received her MD-PhD from Baylor College of Medicine and completed her residency training in Internal Medicine at the University of Texas at Southwestern before moving to Johns Hopkins for a fellowship in Medical Oncology and Hematology. Dr. Emens specializes in cancer immunotherapy, and her research focuses on the development and implementation of breast cancer immunotherapies in combination with traditional anticancer therapies and newer targeted therapies.